Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (1)	8/15/2005 2:10:20 PM
From: SnowShredder	Read Replies (1) \| Respond to of 251

Entry into Material Agreement, Change in Directors or Principal Officer biz.yahoo.com fwiw...Just parking. Best of Luck, SS >>>> Form 8-K for CYTORI THERAPEUTICS, INC. -------------------------------------------------------------------------------- 15-Aug-2005 Entry into Material Agreement, Change in Directors or Principal Officer Item 1.01 Entry into a Material Definitive Agreement On August 10, 2005, we entered into a Severance Agreement and Mutual Release with Sharon V. Schulzki, who had been our Chief Operating Officer. In the agreement, the parties terminated their employment relationship and gave releases to each other. We agreed to pay Ms. Schulzki $155,164 (seven months' salary) and extend to August 5, 2007 the post-separation exercisability period of her 253,743 vested stock options. Her unvested stock options terminated in accordance with their terms. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Sharon V. Schulzki, Chief Operating Officer of Cytori Therapeutics, Inc., ceased employment with the Company on August 10, 2005, and the Company does not intend to refill this position due to the shifting of business focus toward the regenerative cell technology platform.